PURPOSE: Pregabalin is a gamma-aminobutyric acid (GABA) analogue approved for the treatment of epilepsy, neuropathic pain and generalised anxiety disorder. As a GABA analogue, there has been some concern about an abuse liability. We aimed to investigate the possible abuse liability of pregabalin. METHODS: By applying a Bayesian data-mining algorithm to reports of possible drug abuse or addiction in the Swedish national register of adverse drug reactions (SWEDIS), we calculated the information component (IC) for pregabalin and reports of abuse and addiction. RESULTS: Out of 198 reports indicative of abuse or addiction to any drug, 16 concerned pregabalin. The IC became significantly elevated in the fourth quarter of 2008, rising to 3.99 (95% confidence interval 3.21-4.59) at the end of 2009. CONCLUSION: Based on the signal from the present study, we conclude that pregabalin is likely to be associated with an abuse potential.
PURPOSE: Pregabalin is a gamma-aminobutyric acid (GABA) analogue approved for the treatment of epilepsy, neuropathic pain and generalised anxiety disorder. As a GABA analogue, there has been some concern about an abuse liability. We aimed to investigate the possible abuse liability of pregabalin. METHODS: By applying a Bayesian data-mining algorithm to reports of possible drug abuse or addiction in the Swedish national register of adverse drug reactions (SWEDIS), we calculated the information component (IC) for pregabalin and reports of abuse and addiction. RESULTS: Out of 198 reports indicative of abuse or addiction to any drug, 16 concerned pregabalin. The IC became significantly elevated in the fourth quarter of 2008, rising to 3.99 (95% confidence interval 3.21-4.59) at the end of 2009. CONCLUSION: Based on the signal from the present study, we conclude that pregabalin is likely to be associated with an abuse potential.
Authors: A Bate; M Lindquist; I R Edwards; S Olsson; R Orre; A Lansner; R M De Freitas Journal: Eur J Clin Pharmacol Date: 1998-06 Impact factor: 2.953
Authors: V Pauly; M Lapeyre-Mestre; D Braunstein; M Rueter; X Thirion; E Jouanjus; J Micallef Journal: Eur J Clin Pharmacol Date: 2014-11-20 Impact factor: 2.953
Authors: Maximilian Gahr; Roland W Freudenmann; Christoph Hiemke; Makus A Kölle; Carlos Schönfeldt-Lecuona Journal: Eur J Clin Pharmacol Date: 2013-01-05 Impact factor: 2.953